The evolving landscape of the animal model market reflects expanding applications in pharmaceutical development, biomedical research, and toxicology testing. Increasing R&D investments and advancements in genetic engineering continue to drive transformational shifts, shaping the industry size and market growth patterns through 2032.
Market Size and Overview
The global animal model market size is estimated to be valued at USD 1,577.30 million in 2025 and is expected to reach USD 2,394.30 million by 2032, exhibiting a compound annual growth rate (CAGR) of 6.0% from 2025 to 2032. Animal Model Market Growth aligns with rising demand for reliable preclinical testing platforms and growing adoption of advanced disease models for translational research. These factors emphasize positive market revenue trajectories and reveal promising market opportunities across life sciences sectors.
Market Segments
The animal model market encompasses three core segment categories: model type, application, and end-user industries. Within model types, genetically engineered models dominate due to precision in mimicking human disease states, with CRISPR-based models emerging as the fastest-growing sub-segment—witnessing a 12% increase in adoption in 2024, driven by enhanced genome editing capabilities. In applications, drug discovery remains the largest segment, while safety and toxicity testing exhibit rapid growth fueled by regulatory emphasis on animal welfare and alternative testing standards. End users chiefly include pharmaceutical companies, academic research institutes, and biotechnology firms, among which pharmaceutical companies exhibit substantial market revenue growth supported by intensive preclinical pipeline activities.
Market Drivers
A principal market driver is the advancement in genetically engineered animal models, fueled by improvements in gene-editing technologies such as CRISPR and TALEN. In 2024, over 40% of new animal model developments incorporated these technologies, enabling more accurate disease modeling and facilitating accelerated drug discovery processes worldwide. Policy shifts encouraging ethical research frameworks and refinement of animal welfare regulations also propel innovation within the animal model industry size, emphasizing the importance of technologically advanced and humane experimental designs.
Segment Analysis
Focusing on the model type segment, genetically engineered models accounted for the majority of market revenue in 2024, with traditional models retaining steady use. The precision provided by CRISPR-modified mice fosters faster drug validation timelines, manifesting a revenue growth of approximately 14% year-on-year. Case studies from leading pharmaceutical R&D centers illustrate a 20% reduction in experimental errors when leveraging genetically engineered models, underscoring their increasing market scope and attractiveness among market players aiming for cost-effective preclinical testing solutions.
Consumer Behaviour Insights
Recent consumer behavior insights reveal significant movement towards customization and enhanced model specificity. In 2024, surveys covering biotech firm preferences indicated a 35% rise in demand for tailor-made animal models to match niche pathological conditions. Additionally, sustainability concerns are influencing purchasing decisions, with 28% of researchers prioritizing models developed under refined ethical standards or reduced animal use protocols. Digital consumption patterns also affect procurement behavior; online platforms providing detailed model databases and accelerated ordering processes accounted for a 22% increase in adoption rates, reflecting a market trend toward digital integration for improved accessibility and efficiency.
Key Players
Leading companies shaping the animal model market include Charles River Laboratories International, Envigo, Taconic Biosciences, Jackson Laboratory, Envigo CRS, Biomere, and others totaling over 15 notable firms. In 2024–2025, many market players expanded capacity to meet growing demands; Charles River Laboratories launched new transgenic lines and expanded their genomic services, capturing key contracts in Asia-Pacific. Similarly, Taconic Biosciences increased regional presence through strategic acquisitions in Europe, enhancing service portfolios and operational agility. These activities demonstrate coherent alignment with market growth strategies and reflect broader industry trends of consolidation and technological innovation.
Key Winning Strategies Adopted by Key Players
Among impactful strategies, Charles River Laboratories in 2025 employed AI-driven model selection platforms to optimize preclinical experiment design, reducing time-to-data by 30%. This innovation set new operational benchmarks far beyond standard practices. Another notable case includes Envigo’s adoption of co-development partnerships with biotech startups in 2024, accelerating novel model commercialization and accessing cutting-edge genetic editing pipelines, significantly boosting revenue streams. Lastly, Jackson Laboratory strategically introduced modular breeding programs tailored for rare disease models, achieving improved customization and cost efficiency, which enhanced their market presence and differentiated their service offerings in a competitive landscape.
FAQs
1. Who are the dominant players in the animal model market?
Key players include Charles River Laboratories International, Taconic Biosciences, Jackson Laboratory, and Envigo, with several adopting innovative genetic editing and regional expansion strategies in 2024-2025.
2. What will be the size of the animal model market in the coming years?
The market is projected to grow from USD 1,577.30 million in 2025 to approximately USD 2,394.30 million by 2032, with a steady CAGR of 6.0%.
3. Which end-user industry has the largest growth opportunity?
Pharmaceutical companies represent the largest growth opportunity due to expanding drug discovery pipelines and increased reliance on genetically engineered models for preclinical testing.
4. How will market development trends evolve over the next five years?
Advances in gene editing technologies, along with increasing digital adoption for model procurement and sustainability-driven product development, will dominate market trends and drive the industry size.
5. What is the nature of the competitive landscape and challenges in the animal model market?
The landscape is highly competitive with rapid innovation, though challenges include regulatory compliance and ethical considerations driving shifts toward alternative models and refined animal use protocols.
6. What go-to-market strategies are commonly adopted in the animal model market?
Market players frequently use capacity expansions, technology partnerships, AI integration for model optimization, and customized breeding programs to enhance business growth and market dynamics.
Get more insights on, Animal Model Market
Get This Report in Japanese Language: 動物モデル市場
Get This Report in Korean Language: 동물 모델 시장
Read More Articles Related to this Industry- Key Parameters Measured by Blood Gas Analyzers and Their Clinical Significance
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
Comments
0 comment